The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Abstract
The elucidation of the human genome sequence has made it possible to identify genetic alterations in cancers in unprecedented detail. To begin a systematic analysis of such alterations, we determined the sequence of well-annotated human protein-coding genes in two common tumor types. Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ∼90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention, and open fertile avenues for basic research in tumor biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citationBase-Calling of Automated Sequencer Traces Using Phred. II. Error Probabilities
Ewing, B., & Green, P. (1998) · Genome Research · doi:10.1101/gr.8.3.186 · Cited by 5,439
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Self-citationGenetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., et al. (1995) · Science · doi:10.1126/science.7761852 · Cited by 2,270
Self-citationIntegrated Genomic and Proteomic Analyses of a Systematically Perturbed Metabolic Network
Ideker, T., Thorsson, V., Ranish, J. A., Christmas, R., Buhler, J., Eng, J. K., Bumgarner, R., Goodlett, D. R., Aebersold, R., & Hood, L. (2001) · Science · doi:10.1126/science.292.5518.929 · Cited by 2,050
Prevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860
Self-citationLandis, C. A., Masters, S. B., Spada, A., Pace, A. M., Bourne, H. R., & Vallar, L. (1989) · Nature · doi:10.1038/340692a0 · Cited by 1,441
Cited by
Items 201–300 of 351
Cancer Proliferation Gene Discovery Through Functional Genomics
Schlabach, M. R., Luo, J., Solimini, N. L., Hu, G., Xu, Q., Li, M. Z., Zhao, Z., Smogorzewska, A., Sowa, M. E., Ang, X. L., et al. (2008) · Science · doi:10.1126/science.1149200 · Cited by 380
Germline mutations in TMEM127 confer susceptibility to pheochromocytoma
Qin, Y., Yao, L., King, E. E., Buddavarapu, K., Lenci, R. E., Chocron, E. S., Lechleiter, J. D., Sass, M., Aronin, N., Schiavi, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.533 · Cited by 379
Cook, D. R., Rossman, K. L., & Der, C. J. (2014) · Oncogene · doi:10.1038/onc.2013.362 · Cited by 378
Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, S. G., & Biswal, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0589 · Cited by 374
IDH mutations in glioma and acute myeloid leukemia
Dang, L., Jin, S., & Su, S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 370
Singh, A., Boldin-Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J., Blackford, A., Goodman, S. N., Bunz, F., Watson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1401 · Cited by 367
GRØNBÆK, K., HOTHER, C., & JONES, P. A. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_636.xml.x · Cited by 366
Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells
Solimini, N. L., Luo, J., & Elledge, S. J. (2007) · Cell · doi:10.1016/j.cell.2007.09.007 · Cited by 365
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing
Campbell, P. J., Pleasance, E. D., Stephens, P. J., Dicks, E., Rance, R., Goodhead, I., Follows, G. A., Green, A. R., Futreal, P. A., & Stratton, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801523105 · Cited by 365
Bleeker, F. E., Lamba, S., Leenstra, S., Troost, D., Hulsebos, T., Vandertop, W. P., Frattini, M., Molinari, F., Knowles, M., Cerrato, A., et al. (2009) · Human Mutation · doi:10.1002/humu.20937 · Cited by 363
Wnt signaling in adult intestinal stem cells and cancer
Krausova, M., & Korinek, V. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2013.11.032 · Cited by 361
The nuclear envelope environment and its cancer connections
Chow, K.-H., Factor, R. E., & Ullman, K. S. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3219 · Cited by 359
Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Pires, M. M., Maurer, M., Holm, K., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.39 · Cited by 355
Oxidative stress in environmental-induced carcinogenesis
Mena, S., Ortega, A., & Estrela, J. M. (2009) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2008.09.017 · Cited by 355
Human cancers express a mutator phenotype
Bielas, J. H., Loeb, K. R., Rubin, B. P., True, L. D., & Loeb, L. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607057103 · Cited by 354
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
Self-citationA pathway-based classification of human breast cancer
Gatza, M. L., Lucas, J. E., Barry, W. T., Kim, J. W., Wang, Q., D. Crawford, M., B. Datto, M., Kelley, M., Mathey-Prevot, B., Potti, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912708107 · Cited by 347
Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer
Schuebel, K. E., Chen, W., Cope, L., Glöckner, S. C., Suzuki, H., Yi, J.-M., Chan, T. A., Neste, L. V., Criekinge, W. V., Bosch, S. V. D., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030157 · Cited by 347
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J.-J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 345
Chen, W. W., Balaj, L., Liau, L. M., Samuels, M. L., Kotsopoulos, S. K., Maguire, C. A., LoGuidice, L., Soto, H., Garrett, M., Zhu, L. D., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.28 · Cited by 343
Morin, R. D., Bainbridge, M., Fejes, A., Hirst, M., Krzywinski, M., Pugh, T. J., McDonald, H., Varhol, R., Jones, S. J. M., & Marra, M. A. (2008) · BioTechniques · doi:10.2144/000112900 · Cited by 342
Self-citationDefining ‘chromosomal instability’
Geigl, J. B., Obenauf, A. C., Schwarzbraun, T., & Speicher, M. R. (2008) · Trends in Genetics · doi:10.1016/j.tig.2007.11.006 · Cited by 341
Therapeutic targeting of EPH receptors and their ligands
Boyd, A. W., Bartlett, P. F., & Lackmann, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4175 · Cited by 341
Novellasdemunt, L., Antas, P., & Li, V. S. W. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00117.2015 · Cited by 339
Epigenomic Enhancer Profiling Defines a Signature of Colon Cancer
Akhtar-Zaidi, B., Cowper-Sal·lari, R., Corradin, O., Saiakhova, A., Bartels, C. F., Balasubramanian, D., Myeroff, L., Lutterbaugh, J., Jarrar, A., Kalady, M. F., et al. (2012) · Science · doi:10.1126/science.1217277 · Cited by 339
Self-citationMaking sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution
Yang, D., Jones, M. G., Naranjo, S., Rideout, W. M., Min, K. H. (., Ho, R., Wu, W., Replogle, J. M., Page, J. L., Quinn, J. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.015 · Cited by 334
Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis
Singh, A., Happel, C., Manna, S. K., Acquaah-Mensah, G., Carrerero, J., Kumar, S., Nasipuri, P., Krausz, K. W., Wakabayashi, N., Dewi, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66353 · Cited by 333
Evidence for Editing of Human Papillomavirus DNA by APOBEC3 in Benign and Precancerous Lesions
Vartanian, J.-P., Guétard, D., Henry, M., & Wain-Hobson, S. (2008) · Science · doi:10.1126/science.1153201 · Cited by 331
Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer
Bishayee, A. (2011) · Frontiers in Bioscience · doi:10.2741/3730 · Cited by 330
Mlecnik, B., Tosolini, M., Charoentong, P., Kirilovsky, A., Bindea, G., Berger, A., Camus, M., Gillard, M., Bruneval, P., Fridman, W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.057 · Cited by 328
SMAD2,SMAD3 and SMAD4 Mutations in Colorectal Cancer
Fleming, N. I., Jorissen, R. N., Mouradov, D., Christie, M., Sakthianandeswaren, A., Palmieri, M., Day, F., Li, S., Tsui, C., Lipton, L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2706 · Cited by 324
Chin, S. F., Teschendorff, A. E., Marioni, J. C., Wang, Y., Barbosa-Morais, N. L., Thorne, N. P., Costa, J. L., Pinder, S. E., van de Wiel, M. A., Green, A. R., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-10-r215 · Cited by 324
Hereditary breast cancer: new genetic developments, new therapeutic avenues
Campeau, P. M., Foulkes, W. D., & Tischkowitz, M. D. (2008) · Human Genetics · doi:10.1007/s00439-008-0529-1 · Cited by 320
Evolution in Health and Disease
(2007) · doi:10.1093/acprof:oso/9780199207466.001.0001 · Cited by 320
Ng, P. C., & Kirkness, E. F. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60327-367-1_12 · Cited by 320
Impact of deleterious passenger mutations on cancer progression
McFarland, C. D., Korolev, K. S., Kryukov, G. V., Sunyaev, S. R., & Mirny, L. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213968110 · Cited by 317
Advances in Chemical Carcinogenesis: A Historical Review and Prospective
Loeb, L. A., & Harris, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2852 · Cited by 317
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
He, J., Abdel-Wahab, O., Nahas, M. K., Wang, K., Rampal, R. K., Intlekofer, A. M., Patel, J., Krivstov, A., Frampton, G. M., Young, L. E., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664649 · Cited by 311
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M., Olzscha, H., & La Thangue, N. B. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 310
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
Bass, A. J., Lawrence, M. S., Brace, L. E., Ramos, A. H., Drier, Y., Cibulskis, K., Sougnez, C., Voet, D., Saksena, G., Sivachenko, A., et al. (2011) · Nature Genetics · doi:10.1038/ng.936 · Cited by 309
Leary, R. J., Lin, J. C., Cummins, J., Boca, S., Wood, L. D., Parsons, D. W., Jones, S., Sjöblom, T., Park, B.-H., Parsons, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808041105 · Cited by 306
Self-citationRole of mitochondrial dysfunction in cancer progression
Hsu, C.-C., Tseng, L.-M., & Lee, H.-C. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216641787 · Cited by 305
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Konecny, G. E., Winterhoff, B., Kolarova, T., Qi, J., Manivong, K., Dering, J., Yang, G., Chalukya, M., Wang, H.-J., Anderson, L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2307 · Cited by 302
Self-citationDistinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
Hollestelle, A., Nagel, J. H. A., Smid, M., Lam, S., Elstrodt, F., Wasielewski, M., Ng, S. S., French, P. J., Peeters, J. K., Rozendaal, M. J., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0460-8 · Cited by 301
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R. (2010) · Oncogene · doi:10.1038/onc.2010.444 · Cited by 296
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3342 · Cited by 288
Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J. A., Solit, D. B., Paty, P. B., Rohle, D., Vivanco, I., Chmielecki, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900571106 · Cited by 299
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 298
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 297
Parkinson, C. A., Gale, D., Piskorz, A. M., Biggs, H., Hodgkin, C., Addley, H., Freeman, S., Moyle, P., Sala, E., Sayal, K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002198 · Cited by 297
Sur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 295
Self-citationOncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291
MAEDA, H. (2012) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.88.53 · Cited by 291
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
Gorrini, C., Baniasadi, P. S., Harris, I. S., Silvester, J., Inoue, S., Snow, B., Joshi, P. A., Wakeham, A., Molyneux, S. D., Martin, B., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121337 · Cited by 289
“…mutations are rare, genome-wide sequencing of human breast cancers identified a KEAP1 mutation (C23Y) that disrupts its interaction with NRF2, leading to increased NRF2 protein stability and antioxidant signaling in a subset of human breast cancers (Sjöblom et al., 2006; Nioi and Nguyen, 2007).”
BackgroundMarked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Valeri, N., Braconi, C., Gasparini, P., Murgia, C., Lampis, A., Paulus-Hock, V., Hart, J. R., Ueno, L., Grivennikov, S. I., Lovat, F., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.006 · Cited by 286
The N‐myc downstream regulated gene (NDRG) family: diverse functions, multiple applications
Melotte, V., Qu, X., Ongenaert, M., van Criekinge, W., de Bruïne, A. P., Baldwin, H. S., & van Engeland, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-151464 · Cited by 285
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Lee, J. Y., Lee, H. T., Shin, W., Chae, J., Choi, J., Kim, S. H., Lim, H., Won Heo, T., Park, K. Y., Lee, Y. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms13354 · Cited by 285
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types
Jones, S., Li, M., Parsons, D. W., Zhang, X., Wesseling, J., Kristel, P., Schmidt, M. K., Markowitz, S., Yan, H., Bigner, D., et al. (2012) · Human Mutation · doi:10.1002/humu.21633 · Cited by 285
Self-citationRadiation and immunotherapy: a synergistic combination
Kalbasi, A., June, C. H., Haas, N., & Vapiwala, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69219 · Cited by 284
Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing
Hoang, M. L., Chen, C.-H., Sidorenko, V. S., He, J., Dickman, K. G., Yun, B. H., Moriya, M., Niknafs, N., Douville, C., Karchin, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006200 · Cited by 284
Self-citationAntioxidants from Plants Protect against Skin Photoaging
Petruk, G., Del Giudice, R., Rigano, M. M., & Monti, D. M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1454936 · Cited by 283
Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy
Cullup, T., Kho, A. L., Dionisi-Vici, C., Brandmeier, B., Smith, F., Urry, Z., Simpson, M. A., Yau, S., Bertini, E., McClelland, V., et al. (2013) · Nature Genetics · doi:10.1038/ng.2497 · Cited by 282
Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis
Herceg, Z., & Hainaut, P. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.004 · Cited by 282
Plakins in development and disease
Sonnenberg, A., & Liem, R. K. H. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.03.039 · Cited by 281
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Marks, P. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.510514 · Cited by 281
Accessorizing and anchoring the LINC complex for multifunctionality
Chang, W., Worman, H. J., & Gundersen, G. G. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201409047 · Cited by 281
Precision Oncology: Who, How, What, When, and When Not?
Schwartzberg, L., Kim, E. S., Liu, D., & Schrag, D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174176 · Cited by 278
Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease−Associated Colorectal Cancers
Robles, A. I., Traverso, G., Zhang, M., Roberts, N. J., Khan, M. A., Joseph, C., Lauwers, G. Y., Selaru, F. M., Popoli, M., Pittman, M. E., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.036 · Cited by 276
Self-citationSystematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers
Reimand, J., & Bader, G. D. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.68 · Cited by 275
The WNKs: Atypical Protein Kinases With Pleiotropic Actions
McCormick, J. A., & Ellison, D. H. (2011) · Physiological Reviews · doi:10.1152/physrev.00017.2010 · Cited by 274
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer
Weigelt, B., & Bissell, M. J. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.013 · Cited by 273
4E-Binding Protein 1: A Key Molecular “Funnel Factor” in Human Cancer with Clinical Implications
Armengol, G., Rojo, F., Castellví, J., Iglesias, C., Cuatrecasas, M., Pons, B., Baselga, J., & Ramón y Cajal, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0881 · Cited by 270
Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis
Fang, F., Turcan, S., Rimner, A., Kaufman, A., Giri, D., Morris, L. G. T., Shen, R., Seshan, V., Mo, Q., Heguy, A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001875 · Cited by 267
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S. J., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266
Feng, Z., Hu, W., Teresky, A. K., Hernando, E., Cordon-Cardo, C., & Levine, A. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708043104 · Cited by 264
TGF-β signaling alterations and susceptibility to colorectal cancer
Xu, Y., & Pasche, B. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl486 · Cited by 264
Killela, P. J., Pirozzi, C. J., Healy, P., Reitman, Z. J., Lipp, E., Rasheed, B. A., Yang, R., Diplas, B. H., Wang, Z., Greer, P. K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1765 · Cited by 263
A New Mutational aktivation in the PI3K Pathway
Brugge, J., Hung, M.-C., & Mills, G. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.014 · Cited by 263
A map of human cancer signaling
Cui, Q., Ma, Y., Jaramillo, M., Bari, H., Awan, A., Yang, S., Zhang, S., Liu, L., Lu, M., O'Connor‐McCourt, M., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100200 · Cited by 262
Does the Immune System Naturally Protect Against Cancer?
Corthay, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00197 · Cited by 261
Arndt, G. M., Dossey, L., Cullen, L. M., Lai, A., Druker, R., Eisbacher, M., Zhang, C., Tran, N., Fan, H., Retzlaff, K., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-374 · Cited by 260
Identification of high-quality cancer prognostic markers and metastasis network modules
Li, J., Lenferink, A. E. G., Deng, Y., Collins, C., Cui, Q., Purisima, E. O., O'Connor-McCourt, M. D., & Wang, E. (2010) · Nature Communications · doi:10.1038/ncomms1033 · Cited by 258
Agrawal, N., Jiao, Y., Sausen, M., Leary, R., Bettegowda, C., Roberts, N. J., Bhan, S., Ho, A. S., Khan, Z., Bishop, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2703 · Cited by 255
Self-citationHouse, C. D., Vaske, C. J., Schwartz, A. M., Obias, V., Frank, B., Luu, T., Sarvazyan, N., Irby, R., Strausberg, R. L., Hales, T. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1169 · Cited by 254
Precision oncology: origins, optimism, and potential
Prasad, V., Fojo, T., & Brada, M. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00620-8 · Cited by 254
Epigenetics and Colorectal Cancer Pathogenesis
Bardhan, K., & Liu, K. (2013) · Cancers · doi:10.3390/cancers5020676 · Cited by 252
Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?
Kloosterhof, N. K., Bralten, L. B., Dubbink, H. J., French, P. J., & van den Bent, M. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70053-x · Cited by 222
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220
NALP Inflammasomes: a central role in innate immunity
Martinon, F., Gaide, O., Pétrilli, V., Mayor, A., & Tschopp, J. (2007) · Seminars in Immunopathology · doi:10.1007/s00281-007-0079-y · Cited by 218
“Some studies have also identified NALPs as possible candidate genes involved in cancer [139], or in some forms of cell death [41, 152].”
BackgroundA mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity
Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212
Kloosterman, W. P., Hoogstraat, M., Paling, O., Tavakoli-Yaraki, M., Renkens, I., Vermaat, J. S., van Roosmalen, M. J., van Lieshout, S., Nijman, I. J., Roessingh, W., et al. (2011) · Genome Biology · doi:10.1186/gb-2011-12-10-r103 · Cited by 204
PTPN14 interacts with and negatively regulates the oncogenic function of YAP
Liu, X., Yang, N., Figel, S. A., Wilson, K. E., Morrison, C. D., Gelman, I. H., & Zhang, J. (2013) · Oncogene · doi:10.1038/onc.2012.147 · Cited by 196
Survival improvement for patients with metastatic colorectal cancer over twenty years
Zeineddine, F. A., Zeineddine, M. A., Yousef, A., Gu, Y., Chowdhury, S., Dasari, A., Huey, R. W., Johnson, B., Kee, B., Lee, M. S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00353-4 · Cited by 192
Self-citationWhat would you do if you could sequence everything?
Kahvejian, A., Quackenbush, J., & Thompson, J. F. (2008) · Nature Biotechnology · doi:10.1038/nbt1494 · Cited by 189
Ion channel expression as promising cancer biomarker
Lastraioli, E., Iorio, J., & Arcangeli, A. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.12.016 · Cited by 187
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Evolution of the cancer genome
Podlaha, O., Riester, M., De, S., & Michor, F. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.01.003 · Cited by 188
Metadata
- Authors
- Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C., Meeh, P., Markowitz, S. D., Willis, J., Dawson, D., Willson, J. K. V., Gazdar, A. F., Hartigan, J., Wu, L., Liu, C., Parmigiani, G., Park, B. H., Bachman, K. E., Papadopoulos, N., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E.
- Venue
- Science
- Published
- 2006-10-13
- Volume
- 314
- Issue
- 5797
- Pages
- 268-274
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4240237951
- Cited by
- 3,169
- References
- 36
- FWCI
- 88.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.